Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
FB

NASDAQ · FBLG

FibroBiologics, Inc. Common Stock

Healthcare · Biotechnology

$0.93

Up+$0.00 (+0.20%)

Updated Oct 31, 2026, 11:43 PM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
14.4M
P/E ratio
-1
Dividend yield
0.00%
52-week range
$0.24 – $5.40
Volume
20.67K
Avg. volume
1.39M

Price performance · FBLG

FBLG price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

FBLG closed at $0.93 after 21 trading sessions, down 25.00% for the selected period.

Last close
$0.93
Period change
-25.00%
Period low
$0.92
Period high
$1.24
Daily close
View OHLC price history
FBLG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$0.92$0.9696$0.90$0.9320.67K
Oct 29, 2026$0.9396$0.9901$0.923$0.928118.07K
Oct 28, 2026$0.9289$0.9934$0.91$0.966732.38K
Oct 27, 2026$0.9704$0.99$0.9294$0.931728.79K
Oct 26, 2026$0.93$0.9498$0.89$0.9399156.67K
Oct 23, 2026$1.02$1.02$0.95$0.95111.92K
Oct 22, 2026$0.97$1.24$0.97$1.02399.07K
Oct 21, 2026$0.90$1.00$0.90$0.993127.51K
Oct 20, 2026$0.93$0.9709$0.8812$0.919994.09K
Oct 19, 2026$0.98$0.98$0.94$0.9441170.33K
Oct 16, 2026$1.02$1.04$0.95$0.97136.02K
Oct 15, 2026$0.96$1.05$0.96$1.00156.2K
Oct 14, 2026$1.00$1.0199$0.9247$0.95109.06K
Oct 13, 2026$1.00$1.025$0.9333$0.959980.69K
Oct 12, 2026$1.12$1.135$0.9893$1.00152.05K
Oct 9, 2026$1.11$1.20$1.10$1.13182.31K
Oct 8, 2026$1.12$1.14$1.05$1.1171.87K
Oct 7, 2026$1.16$1.20$1.07$1.14233.8K
Oct 6, 2026$1.20$1.23$1.12$1.13210.28K
Oct 5, 2026$1.24$1.24$1.18$1.1894.25K
Oct 2, 2026$1.20$1.24$1.10$1.24148.8K

Latest FBLG news

The latest Smart Investors Daily articles mentioning FBLG.

Stock researchCompany · Overview

FBLG research

Overview

Company profile and research snapshot.

Company profile

FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
FBLG recent ratings
DateFirmRatingTarget
Aug 4, 2026HC Wainwright & Co.Buy—
May 4, 2026Maxim GroupHold—
Apr 16, 2026HC Wainwright & Co.Buy—
Mar 26, 2026D. Boral CapitalHold—
Mar 12, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Nikolay Bazhanov, M.D., Ph.D. presented preclinical data on the Company's fibroblast spheroid-derived chondrocyte (FSdC) spheroids for degenerative disc disease (DDD) at the North American

Yahoo · Oct 14, 2026

FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that IP Australia has issued a Notice of Acceptance for Australian Patent Application No. 2024200985, titled "Cellular Blend for the Regeneration of Chondrocytes or Cartilage Type Cells."

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By